VBIO(VBIO)
VBIO
No analyst ratings available
No analyst price targets available for VBIO
Analyst coverage may not be available for this symbol
No recent analyst actions
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 | Q1 2028 | Q2 2028 |
|---|---|---|---|---|---|---|---|---|
| Revenue Avg | $460,000 | $660,000 | $640,000 | $520,000 | $630,000 | $780,000 | $1M | $1M |
| Low | $460,000 | $660,000 | $640,000 | $520,000 | $630,000 | $780,000 | $1M | $1M |
| High | $460,000 | $660,000 | $640,000 | $520,000 | $630,000 | $780,000 | $1M | $1M |
| EBITDA Avg | $91,999 | $131,999 | $127,999 | $103,999 | $125,999 | $155,999 | $265,999 | $213,999 |
| Low | $91,999 | $131,999 | $127,999 | $103,999 | $125,999 | $155,999 | $265,999 | $213,999 |
| High | $91,999 | $131,999 | $127,999 | $103,999 | $125,999 | $155,999 | $265,999 | $213,999 |
| EBIT Avg | $91,999 | $131,999 | $127,999 | $103,999 | $125,999 | $155,999 | $265,999 | $213,999 |
| Low | $91,999 | $131,999 | $127,999 | $103,999 | $125,999 | $155,999 | $265,999 | $213,999 |
| High | $91,999 | $131,999 | $127,999 | $103,999 | $125,999 | $155,999 | $265,999 | $213,999 |
| Net Income Avg | $-47.09B | $-62.79B | $-60.83B | $-21.58B | $-15.70B | $-13.73B | $-13.73B | $-13.73B |
| Low | $-47.09B | $-62.79B | $-60.83B | $-21.58B | $-15.70B | $-13.73B | $-13.73B | $-13.73B |
| High | $-47.09B | $-62.79B | $-60.83B | $-21.58B | $-15.70B | $-13.73B | $-13.73B | $-13.73B |
| EPS Avg | $-408.00 | $-544.00 | $-527.00 | $-187.00 | $-136.00 | $-119.00 | $-119.00 | $-119.00 |
| Low | $-408.00 | $-544.00 | $-527.00 | $-187.00 | $-136.00 | $-119.00 | $-119.00 | $-119.00 |
| High | $-408.00 | $-544.00 | $-527.00 | $-187.00 | $-136.00 | $-119.00 | $-119.00 | $-119.00 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |